CTi Biopharma — Cell Therapeutics — Merger or Acquisition (March 2011)
32 slides from CTi Biopharma's merger presentation, Mar 14, 2011
Slide 1: Tosedostat: Exclusive Marketing License and Co-Development Agreement
Tosedostat Exclusive Marketing License and Co-Development Agreement Exhibit 99.2
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this presentation include statements about future financial and ope
Slide 3: Product/Deal Highlights
Product/Deal Highlights Tosedostat: Novel tumor-selective targeted therapy • Oral, once daily dosing, well tolerated Encouraging phase I/II data • 27% mono-therapy response rate elderly r/r AML • Ongoing trials provide clinical news flow through 2012 Potentially rapid registration timeline: pivotal
Slide 4: Chroma Therapeutics
Chroma Therapeutics Public company expertise in a private company • Seasoned management and Board of Directors • Facilitates co-development interactions and synergies Investor group • Abingworth, Wellcome Trust, Essex Woodlands, Nomura, GSK, Gilde Innovators in new targeted therapies harnessing chro
Slide 5: Tosedostat: Mechanism of Action
Tosedostat: Mechanism of Action - Targets members of aminopeptidase family - Induces genes characteristic of Amino Acid Deprivation response (AADR) - AADR changes only seen in transformed (tumor) cells and not normal cells
Slide 6: Consequences of amino acid deprivation in leukemic cells
Consequences of amino acid deprivation in leukemic cells Cells attempt to solve deficiency (up-regulation of amino acid transporters – AADR response) Cells switch off protein synthesis (e.g. remove mTOR drive) Cells switch on stress-related pathways (NF K B, etc.) Cells produce pro-apoptotic regulat
Slide 7: Tosedostat Clinical Program: Blood-Related Cancers
Tosedostat Clinical Program Blood-Related Cancers
Slide 8: Acute Myeloid Leukemia (AML) Overview
Acute Myeloid Leukemia (AML) Overview One of the most common types of leukemia in adults U.S. Incidence >12,000/yr Median age at diagnosis – 67 years Poor prognostic factors include • Elderly (>60 yo.) • Elevated WBC counts (>100,000/mm ) • Secondary AML resulting from other primary cancers • Histor
Slide 9: Acute Myeloid Leukemia (AML) Overview
Acute Myeloid Leukemia (AML) Overview Cytarabine (Ara-C) and anthracyclines mainstay st line • ~75% relapse within 1 year Approximately 2/3 of elderly patients do not tolerate intensive chemotherapy • 70% of AML patients are >60yrs old • Up to 35% treatment related mortality Significant unmet medica
Slide 10: Phase I/II Clinical Study of Tosedostat in AML and Myelodysplasia
VOLUME 25 . NUMBER 25 - OCTOBER 1 2010 Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia Bob Lowenberg, Gareth Morgan, Gert J. Ossenkoppele, Alan K. Burnett, Pierre Zachée, Ulrich Duhrsen, Daan Dierickx, Carsten Mulle
Slide 11: Phase I/II Study (002)
Phase I/II Study (002) Objectives • Define MTD and anti-leukemic activity of oral Tosedostat Study population • Elderly (>60yrs), r/r AML, MDS, MM not eligible for chemo Phase I (3+3) designed for up to 84 days of dosing • 60mg, 90mg, 130mg, 180mg (oral, 1xdaily) • MTD determined during first 28 day
Slide 12: Phase I/II: Patient characteristics
Phase I/II: Patient characteristics Phase I (n = 16) Phase II (n = 43) Diagnosis No. (%) No. (%) ECOG at baseline No. (%) No. (%)* * Not reported for 1 patient Median age, years (range) 68.4 (45-84) 68 (35-83) Male/Female AML 13 (81.3) 40 (93) MDS 1 (6.3) 3 (7) MM 2 (12.5) 0 (0) 8 (50.0) 16 (37.2) 6
Slide 13: Phase I/II: Patient characteristics (cont)
Phase I/II: Patient characteristics (cont) Phase I (n = 16) Phase II (n = 43) Median time from diagnosis Previous treatment* * Excluding the 2 patients that did not receive CHR-2797 in phase II 3.1 years (0.1-8.8) 7 months (0-39) Untreated 4 (25%) 12 (29.3%) Cytotoxic Therapy 12 (75%) 29 (70.7%) Med
Slide 14: Tosedostat: Treatment duration
Tosedostat: Treatment duration* Dose No. of patients Median duration of therapy, days (range) * Including extended treatment Phase I 60 mg 140 (119-196) 90 mg 40 (13-174) 130 mg 69 (42-222) 180 mg 21 (9-77) Phase II 130 mg 72 (1-471)
Slide 15: Phase I/II: Dose Limiting Toxicities
Phase I/II: Dose Limiting Toxicities DLT Dose No. of patients No. of occurrences The recommended dose of 130 mg for the phase II part was determined during phase I and was based on the following DLT’s: ALT elevation (Grade 3) 130 mg Thrombocytopenia (Grade 4) 180 mg
Slide 16: Most common adverse events in phase I-II
Most common adverse events in phase I-II: time of occurrence Adverse Event (Preferred Term) Incidence Day 1 - 28 Incidence Day 28 - End Patients (n=57) % Patients (n=57) % Fatigue Thrombocytopenia Edema – peripheral Diarrhea Pyrexia Cough Dyspnea Epistaxis Anemia
Slide 17: Phase I/II: Efficacy (response rates)
Phase I/II: Efficacy (response rates) Disease Total # patients CR PR SD Phase I/II AML ORR (CR+PR) 27.5% AML 7* 7** MDS Myeloma * 4 went into remission (duration 4-9 months); 1 cytogenetic response; 1 patient (0101) had a de facto CR (low volume BM tap) ** 1 PR was short
Slide 18: Overall Survival For AML Patients
Overall Survival For AML Patients* Disease Number of patients Median Overall Survival from first treatment with Tosedostat to death, days (range) NR – non responders *Overall survival data for 2 out of the 38 AML patients is not known **Overall survival data for 1 patient unknown JCO 28:4333-4338 Ph
Slide 19: Phase I/II Study (002): Conclusions
Phase I/II Study (002): Conclusions Well-tolerated mono-therapy • Oral once-a-day dosing • Transient reduction in platelets Encouraging phase I/II mono-therapy data • 27% response rate in elderly r/r AML • All responders >60yrs, 79% with r/r disease • Overall survival data encouraging Similar result
Slide 20: Tosedostat Clinical Program: AML Randomized Controlled Trials
Tosedostat Clinical Program Blood Related Cancers - AML Randomized Controlled Trials
Slide 21: Proposed Pivotal Study Design
Proposed Pivotal Study Design Tosedostat + Ara-C 6 months Ara-C 6 months Relapsed/ refractory AML (>60yrs) 35 patients 120 mg 6 months 35 patients 240 mg (2 months) 120 mg (4 months) 120 mg 240/120 mg Complete: Q1 2011 Est. start: Q4 2011 Risk/benefit review, Dose selection
Slide 22: 1st Line AML (HOVON)
1 st Line AML (HOVON) Phase I Assessment of optimal induction dosing regimen Dose-finding Tosedostat + dauno/ara-C Phase II Optimum induction regimen and maintenance Optimal Tosedostat + dauno/ara-C regimen Tosedostat maintenance Standard dauno/ara-C regimen consolidation Arm A Arm B • Patients with
Slide 23: AML Competitive Landscape
AML Competitive Landscape 7 candidates in Phase III mostly cytotoxics Elderly AML life - threatening disease with poor survival (~3 months) low tolerability to chemotherapy • clofarabine iv NDA and laromustine iv NDA: Rejected • Mylotarg® iv approval in relapsed AML: Withdrawn • decitabine iv: Faile
Slide 24: Tosedostat Clinical Program: Other Blood-Related Cancers
Tosedostat Clinical Program Other Blood-Related Cancers Phase I/II
Slide 25: Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS) Disease of elderly : • Lower-risk patients- Lenalidomide; • Higher-risk patients - HSCT (<10%)/ De-methylating agents • Age (>60yrs) – high-intensity therapies not generally offered Unmet medical need: low-intensity therapies with improved efficacy and toxicity profile
Slide 26: Multiple Myeloma (MM)
Multiple Myeloma (MM) Strong biologic and preclinical rationale • Tosedostat inhibits myeloma cell proliferation and induces apoptosis in cell lines and primary patient cells, with minimal effects on bone marrow stroma (Faith Davies) • Tosedostat is synergistic with other anti-myeloma therapies (dex
Slide 27: Tosedostat: Conclusion
Tosedostat: Conclusion Tosedostat is a novel aminopeptidase inhibitor with tumor selective anti-proliferative activity Well-tolerated oral agent (once daily) Demonstrated synergy in combination with currently approved targeted therapies • Bortezomib, decitabine, azacytidine, HDAC inhibitors Potentia
Slide 28: Summary Deal Terms & Structure
Summary Deal Terms & Structure CTI gets exclusive development and marketing rights in the Americas; Chroma retains ROW Cost-sharing • CTI bears 75% of agreed-upon direct development expenses • Trials aimed at US/EU regulatory approval Joint Governance (Development/Marketing Committees) • CTI lead pa
Slide 29: Summary Deal Terms & Structure
Summary Deal Terms & Structure Success-based Milestones • Scaled by number of potential patients in a given indication taking into account line of approval (1 st line Vs r/r) • Successful clinical trial results and NDA approvals • Blood-related cancers - AML, MDS, or Myeloma • Solid Tumor indication
Slide 30: Potential Market Opportunity
Potential Market Opportunity Blood-related Cancers is large US market opportunity • AML ~12,000 pts/yr • MDS ~12,000 pts/yr • Myeloma ~26,000 pts/yr Estimated 2010 WW annual sales for drugs approved/used in AML/MDS or Myeloma • AML/MDS (clofarabine, decitabine, azacytidine) >$ 900 million • Myeloma
Slide 31: Market Opportunity: Current agents
Indication WW 2010 sales* Patent expiration Market Opportunity: Current agents MDS $200MM MDS $534MM Ped. ALL $103MM Multiple Myeloma/Mantle Cell $1.5B Multiple Myeloma/Deletion 5q MDS $2.5B VELCADE *Information from SEC filings.
Slide 32: Summary
Summary Late-stage opportunity potentially addressing unmet medical needs in large markets • Potential 1 st oral non-cytotoxic treatment for AML • Synergistic activity with “blockbuster” products (Velcade®, Dacogen®, Vidaza®, Revlimid®) in MDS, myeloma • Potential rapid registration timeline- pivota
Cell Therapeutics — Merger or Acquisition (March 2011) on 6ix